CD4 and neoplasm: To determine if HSC-derived cells have the capacity to present antigen to CD4+ or CD8+ tumor-specific T cells, HSC-derived cells were again isolated with FACS and either MHC-I or MHC-II was blocked using blocking antibody for culture against effector tumor-specific T cells (Fig. 6b).